All In Biotech

NDA 022075 · Kyowa Kirin

Nourianz

Istradefylline · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Aug 27, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Aug 27, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

28

12 Phase 3, 1 recruiting

FAERS reports

5,984

2,641 serious, 937 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 20, 2025.

NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes. NOURIANZ is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes ( 1 ).

Mechanism: The precise mechanism by which istradefylline exerts its therapeutic effect in Parkinson’s disease is unknown. In in vitro studies and in in vivo animal studies, istradefylline was demonstrated to be an adenosine A 2A receptor antagonist.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 27, 2019 Original approval · Type 1 - New Molecular Entity NovelLabelLetterReview
2 products under this application
  • NOURIANZ · ISTRADEFYLLINE 40MG · TABLET, ORAL · Prescription
  • NOURIANZ · ISTRADEFYLLINE 20MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Istradefylline" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death726
  • drug ineffective634
  • hallucination617
  • dyskinesia484
  • condition aggravated464
  • dizziness423
  • product dose omission issue363
  • constipation357
  • fall352
  • tremor272
  • therapy non-responder252
  • insomnia229

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20144
20152
20162
20175
201825
2019133
20201,509
20211,206
20221,004
2023610
2024678
2025599
2026207

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nourianz (Istradefylline)

2024 spending

$50.7M

Beneficiaries

3,610

19,092 claims

Per beneficiary

$14,050

$62.73 per unit

View as table
YearSpending
2020$19,460,895
2021$37,530,854
2022$45,127,244
2023$49,718,992
2024$50,721,486

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 26 on PubMed

Sponsor: Kyowa Kirin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.